{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:31:00Z","timestamp":1760783460852},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,11,12]],"date-time":"2011-11-12T00:00:00Z","timestamp":1321056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ninety\u2010four Mayo Clinic patients with myelofibrosis (MF) participated in two consecutive clinical trials of pomalidomide (0.5\u20133.5 mg\/day), with or without prednisone. Overall anemia response was 27% and increased to 53% in <jats:italic>JAK2<\/jats:italic>V617F\u2010positive patients with &lt;10 cm palpable splenomegaly and &lt;5% circulating blasts; response rate was 0% in mutation\u2010negative patients with either \u226510 cm splenomegaly or \u22655% circulating blasts (<jats:italic>P<\/jats:italic> = 0.0001). Median duration of anemia response was 16 months. Treatment effect on splenomegaly was negligible. To date, pomalidomide therapy has been discontinued in 86 (91%) patients at a rate of 68% at 1 year and 89% at 2 years. Grade 1 sensory neuropathy developed in 4 (13%) of 30 patients treated for \u22651 year. Risk\u2010adjusted survival in pomalidomide\u2010treated primary MF patients (<jats:italic>n<\/jats:italic> = 72) was similar to their counterparts not exposed to the drug (<jats:italic>n<\/jats:italic> = 471; <jats:italic>P<\/jats:italic> = 0.19). Long\u2010term follow\u2010up of pomalidomide treatment in MF reveals palliative value for a select group of patients and treatment\u2010emergent sensory neuropathy. Am. J. Hematol. 2012. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.22233","type":"journal-article","created":{"date-parts":[[2011,10,23]],"date-time":"2011-10-23T04:56:46Z","timestamp":1319345806000},"page":"66-68","source":"Crossref","is-referenced-by-count":55,"title":["Long\u2010term outcome of pomalidomide therapy in myelofibrosis"],"prefix":"10.1002","volume":"87","author":[{"given":"Kebede H.","family":"Begna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1323"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21827"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004572"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7356"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03443.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2928"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.160"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-287417"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6548"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404711"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-325589"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21892"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21598"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.254"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21972"},{"key":"e_1_2_5_18_2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymhoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.22233","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.22233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:55:35Z","timestamp":1698785735000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.22233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,12]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/ajh.22233"],"URL":"https:\/\/doi.org\/10.1002\/ajh.22233","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,12]]}}}